TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A non-peer-reviewed preprint reports that donor hearts showed molecular aging or rejuvenation signatures associated with the recipient’s age in mouse experiments and a small human biopsy sample. The findings do not show that a heart’s function or a recipient’s health improves because of this shift, and they are not ready to guide clinical decisions.
A non-peer-reviewed preprint reports that transplanted hearts showed molecular signatures associated with the biological age of their recipients, including signs consistent with rejuvenation in older hearts placed in younger mice. The researchers also found a similar age-related pattern in a small set of human heart biopsies, but the results do not establish that older donor hearts become healthier or that recipients gain a clinical benefit.
Teams led by researchers at Brigham and Women’s Hospital and Harvard Medical School studied age-mismatched heart transplants in mice, then examined archived human biopsy samples and clinical outcomes. The work, titled “Transplanted hearts assimilate the recipient’s biological age,” is available as a bioRxiv preprint. Because it has not been peer-reviewed, its findings should be treated as preliminary, not as established evidence or guidance for medical care.
In the mouse experiments, researchers assessed DNA methylation markers four to six months after transplantation. Biological-age estimates for donor hearts were associated with recipients’ ages: younger hearts in older mice showed signatures consistent with aging, while older hearts in younger mice showed signatures consistent with rejuvenation. Analyses of gene activity found related patterns, including changes involving inflammation and mitochondrial processes. The recipient mice’s own heart, liver and blood generally showed little change in biological-age estimates.
The human analysis involved archived heart-biopsy samples from 11 transplant recipients, whose donor and recipient ages differed by between 24 years in one direction and 50 years in the other. The researchers reported a pattern similar to the mouse findings, with estimated biological age in the transplanted hearts associated with recipient age. In a separate analysis of outcomes among hundreds of recipients one year after transplant, recipient age was associated with several measures, most consistently exercise capacity. These observations do not show that molecular age shifts caused differences in function.
Could Age-Mismatched Donors Expand Supply?
Heart transplantation is constrained by a shortage of donor organs, so evidence that a transplanted heart’s molecular features can change in its recipient may be relevant to research on the use of donor hearts across age groups. The study raises the possibility that donor age alone may not capture how an organ’s biology changes after transplantation.
That possibility remains a research question, not a basis for changing donor-selection practices. The study does not show that older hearts are equivalent to younger hearts, that molecular rejuvenation improves survival or long-term function, or that age-related risks can be offset by a younger recipient. Any change to transplant decisions would require stronger clinical evidence and expert review.
As an affiliate, we earn on qualifying purchases.
Why Researchers Studied Age Mismatch
Transplant programs face persistent demand for donor hearts. The report notes that the number of U.S. heart-transplant recipients aged 65 or older rose 127% from 2010 to 2021, while the supply of available organs remains limited. Although there is no official upper age limit for heart donors, younger donors are generally recommended, and relatively few programs accept hearts from donors older than 50, according to the source report.
Prior research into exposure to younger organisms’ blood and systemic factors has prompted interest in whether age-related features can shift across an age mismatch. This study tests that idea in transplanted hearts. It used a heterotopic mouse transplant model, in which the recipient kept its own heart while a donor heart was connected to blood vessels, alongside human biopsy data. The different components provide evidence at different levels; neither the mouse model nor the small biopsy sample can by itself establish what should happen in clinical practice.
“The biological age of heterochronic heart implants is strongly affected by the recipient’s age.”
— The study authors, as summarized in the News-Medical report
As an affiliate, we earn on qualifying purchases.
What Molecular Age Cannot Yet Show
The report describes biological-age estimates based on molecular measures, including DNA methylation and gene activity. It does not establish that those estimates correspond to a lasting improvement in the heart’s performance, nor that the observed shifts affect rejection, complications, survival or quality of life. The human biopsy group was small, with 11 recipients, and the available information does not clarify how representative those patients were.
The separate analysis linking recipient age with outcomes such as exercise capacity is observational. It cannot show that a molecular shift caused an outcome, and recipient age may be associated with other factors. The supplied report also does not give enough detail to assess the full methods, limitations or statistical strength of every analysis. The preprint has not undergone peer review, and its claims may change as the work is examined or published.
As an affiliate, we earn on qualifying purchases.
Peer Review and Clinical Follow-Up
The next step is independent scrutiny of the preprint’s methods and findings, followed by confirmation in larger human studies. Research would need to test whether the molecular patterns persist and whether they relate to meaningful clinical outcomes over time, rather than only to estimated biological age or short-term measures.
Until such evidence is available, the findings should not be used to make individual donor or recipient decisions. The source material does not provide a peer-review timetable, a planned publication date or details of a follow-up trial, so those developments remain unknown.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the researchers find?
They reported that the estimated biological age of transplanted hearts was associated with recipients’ age. Older hearts in younger mice showed molecular signatures consistent with rejuvenation, while younger hearts in older mice showed signatures consistent with aging.
Did the study prove that older hearts work better in younger recipients?
No. The findings concern molecular age estimates and related gene-activity patterns. They do not prove that older hearts function better, improve survival or provide a clinical advantage.
Was the research conducted in people?
Partly. The researchers analyzed archived biopsies from 11 transplant recipients and reported a similar age-related pattern. Most of the experimental work described in the report used mice.
Can the results change donor-heart decisions now?
No. The findings are from a preprint that has not been peer-reviewed and are not a basis for clinical guidance. Larger studies would be needed to assess safety and patient outcomes.
What remains unknown?
It is not yet clear whether the molecular changes last, whether they translate into better heart function or health outcomes, or whether the results apply broadly across transplant recipients and donor ages.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
